Logotype for Dimed S.A. Distribuidora de Medicamentos

Dimed (PNVL3) Q1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dimed S.A. Distribuidora de Medicamentos

Q1 2026 earnings summary

25 May, 2026

Executive summary

  • 1Q26 marked the start of a new growth cycle, with strong sales, margin expansion, and operational improvements aligned with the 2030 plan.

  • Retail gross revenue grew 15.1% year-over-year to R$1.56 billion, with digital channels reaching 28.6% of retail revenue.

  • Adjusted EBITDA rose 25.6% year-over-year to R$81.2 million, with margin improving to 5.2%.

  • Adjusted net income increased 38.1% year-over-year to R$38.5 million, with margin at 2.4%.

  • Market share in the Southern Region reached a record 13.3%, with gains across all states and categories.

Financial highlights

  • Consolidated gross revenue: R$1,571 million (+15.8% YoY); retail gross revenue: R$1,555 million (+15.1% YoY).

  • Retail gross margin held at 29.4%, up 14.9% year-over-year.

  • Operational cash generation was R$35.8 million; free cash flow was R$12.4 million, positive for the fifth consecutive quarter.

  • EBITDA 4Wall grew 24.3% year-over-year, reaching a record for the first quarter.

  • Net debt/EBITDA ratio decreased to 0.88x, the lowest in recent quarters.

Outlook and guidance

  • New growth cycle for 2026–2030 initiated, targeting R$11.5–12 billion in revenue and 950–1,000 stores by 2030.

  • EBITDA margin guidance between 6.7%–7% for the period.

  • Continued focus on digitalization, private label expansion, and operational efficiency.

  • Strategic initiatives for 2026 include expanding digital tools, enhancing customer journeys, and deepening loyalty programs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more